Form 8-K · Current Report · Filed 2026-03-03
Roivant Announces $2.25 Billion Settlement with Moderna and New Share Repurchase Program
On March 3, 2026, Roivant Sciences Ltd. announced a significant settlement with Moderna, Inc., resolving patent infringement litigation for $2.25 billion. The settlement includes an upfront payment of $950 million and a contingent payment of up to $1.3 billion based on the outcome of Moderna's appeal regarding Section 1498. Additionally, Roivant's board authorized a new share repurchase program worth up to $1.0 billion, including a previously announced $500 million authorization. The settlement resolves all U.S. and international enforcement actions against Moderna for unauthorized use of lipid nanoparticle delivery technology in its COVID-19 vaccines. The repurchase program is funded by available cash and cash equivalents, with no expiration date, and may be suspended or discontinued at any time.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-26-007548
- CIK
- 0001635088
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$28.10
Next session
+5.1%
Since filing
+23.3%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.